These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 23110505)

  • 1. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
    Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
    Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt demoted in glioblastoma.
    Vogt PK; Hart JR
    Sci Signal; 2009 Apr; 2(67):pe26. PubMed ID: 19383977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
    Fan QW; Cheng CK; Nicolaides TP; Hackett CS; Knight ZA; Shokat KM; Weiss WA
    Cancer Res; 2007 Sep; 67(17):7960-5. PubMed ID: 17804702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
    Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
    Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.
    Halatsch ME; Löw S; Hielscher T; Schmidt U; Unterberg A; Vougioukas VI
    Anticancer Res; 2008; 28(6A):3725-8. PubMed ID: 19189656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
    Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
    Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.
    Howard BM; Gursel DB; Bleau AM; Beyene RT; Holland EC; Boockvar JA
    J Exp Ther Oncol; 2010; 8(3):247-60. PubMed ID: 20734923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
    Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.